Drugs / Lu-PSMA-617
Lu-PSMA-617
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06574880 | May 2025 → Sep 2026 overdue | prostate cancer | Angela Y. Jia, MD PhD | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06852820 | Jun → Dec 2026 expected | hepatocellular carcinoma | Melissa Lumish | Recruiting | No outcome recorded |
| Phase 2 | NCT06738303 | Jul 2025 → Dec 2026 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-09-17 | Novartis Pharmaceuticals | Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021 novartis.com ↗ |
| 2021-06-24 | Novartis Pharmaceuticals | Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine novartis.com ↗ |
| 2021-06-03 | Novartis Pharmaceuticals | Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study novartis.com ↗ |
| 2021-03-23 | Novartis Pharmaceuticals | Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer novartis.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu-PSMA-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06738303 ↗ |
| Known as | 177Lu-PSMA-617 | “The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate...” NCT06852820 ↗ |
| Known as | \[177Lu\]Lu-PSMA-617 | “In HCC, a recent preclinical study demonstrated that radioligand therapy using \[177Lu\]Lu-PSMA-617 and \[177Lu\]Lu-EB-PSMA-617 effectively suppressed tumor growth and...” NCT06852820 ↗ |
| Known as | Lu-177 vipivotide tetraxetan | “The VISION study was a phase 3 trial investigating the efficacy and safety of 177Lu-PSMA-617 (Lu-177 vipivotide tetraxetan) with standard of care in patients with previously...” NCT06852820 ↗ |
| Route | Intravenous | “7.4GBq intravenous infusion once with cycle 1” NCT06574880 ↗ |